RESTORE-IMI 2 phase 3 study of Merck’s RECARBRIO in HABP/VABP meets primary endpoint

This article was originally published here

The global, multicenter, randomized, non-inferiority trial investigated the efficacy and safety of Merck’s antibacterial product RECARBRIO for use in adult patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial

The post RESTORE-IMI 2 phase 3 study of Merck’s RECARBRIO in HABP/VABP meets primary endpoint appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply